Glaucoma LOCI Laboratory
Paul Knepper, MD, PhD, Director
Investigates the cause, prevention, and treatment of primary open-angle Glaucoma (POAG).
Current investigations center on the activation of Toll-like receptor 4 (TLR4), an innate immune receptor, in primary open-angle Glaucoma.
Prevention of degradation of high-molecular-weight hyaluronic acid by a potent hyaluronidase inhibitor, as well as inhibition of TLR4-mediated signaling, could be a novel therapy and the first therapy directly aimed at the cause of POAG.